News Coverage

BioPharm America 2012
EnVivo Pharmaceuticals Named One of the “Fierce 15” Leading Biotech Companies of 2012
Read the Fierce 15 article

Alzheimer’s Association International Conference 2012 (AAIC)
July 2012
Dr. Dana Hilt Presents Positive EVP-6124 Phase 2b Trial Results in Alzheimer’s Disease at AAIC 2012 Press Conference
Watch Press Briefing
View Presentation

About Us
People living with serious brain diseases are deprived of their potential, their relationships, and their very essence. Our ambition is to help them live more fully through the discovery and delivery of life-changing medicines.

People of FORUM

Learn more about our integrated, connected leadership.

Executive Team

Each member of the team brings a unique perspective and expertise, helping to facilitate growth and collaboration within and outside the company.

Deborah Dunsire, MD Christopher L. Burnley Christine A. Carberry Todd Shegog

Dana C. Hilt, MD Maiken Keson-Brookes Gerhard Koenig, PhD Elaine S. Ouellette

Board of Directors

Our team is passionate and dedicated to transforming how people who face debilitating brain diseases can live more fully to actualize more of their potential.

Stephen C. Knight, MD, Chairman Randall Carpenter, MD Deborah Dunsire, MD

John J. Remondi Jennifer Stonestreet Uhrig Robert Weisskoff, PhD

Partners

Partners are vital to our success, and we seek to advance our mission together with partners across the spectrum.

Investors

Our investors take the view that difficult problems require fearless dedication to find solutions.

About Our Images

The vivid images used throughout this site are based on advanced microscopic imaging of neurons that form critical connections within the brain.
Innovation & Pipeline
There are still critical unmet needs facing patients suffering from our most important and challenging brain diseases.

α7 Receptor Agonists

The lead investigational compound for the α7 receptor agonist program is encenicline hydrochloride (EVP-6124).

GSM Program

Gamma secretase modulation (GSM) is a promising new approach to reducing Abeta42 production.

HDAC Program

Unique activity of HDAC may have an important impact on brain diseases that display abnormalities in this gene transcription.

PDE₁₀ Program

FRM-6308 is an investigational phosphodiesterase (PDE) inhibitor that is novel, highly potent and highly selective.
Disease Areas
FORUM Pharmaceuticals understands schizophrenia and Alzheimer’s disease.

Schizophrenia

Schizophrenia is a serious brain disease that can prevent patients from sustaining educational goals or reaching social and occupational milestones.

Alzheimer’s disease

Alzheimer’s disease, a complex neurodegenerative brain disease, is a growing contributor to death and disability in the United States.

Resources

Explore our selection of patient and caregiver resources.
Contact Us
News & Events
See what is happening at FORUM Pharmaceuticals and stay up-to-date on recent scientific publications.

Press Releases

See the latest news from FORUM Pharmaceuticals.

News Coverage

Updates on media coverage of our company and our research.

Events

See what is happening and view upcoming events.

Publications

Scientific articles and presentations.
Careers
Globals
Contact Us
Terms
Privacy Policy